Medstar National Rehabilitation Hospital
Washington D.C., District of Columbia, 20010, United States
Location status: Recruiting
Location contact
Christopher Riegner, MPH
CONTACT
Inger Ljungberg, MPH
CONTACT
NCT Number: NCT07390591
The goal of this observational qualitative study is to learn about the experiences and perspectives of patients with neurogenic lower urinary tract dysfunction (NLUTD) and their caregivers regarding different types of intravesical instillations used for urinary health. The study aims to understand the perceived benefits, challenges, and opportunities related to Lactobacillus-only, gentamicin-only, and combined gentamicin-Lactobacillus instillations. The main question this study seeks to answer is:
1. Determine patient and caregivers' preferences, and overall experiences regarding intravesical therapeutics for urinary symptoms and UTI
Researchers will compare responses from four groups: participants who have used Lactobacillus-only instillations, gentamicin-only instillations, combined gentamicin-Lactobacillus instillations, and caregivers who have experience supporting instillations.
Participants will take part in a one-hour semi-structured interview and may be contacted for brief follow-up discussions to clarify findings. Interviews will be audio-recorded, transcribed, and analyzed using qualitative data software to identify themes related to treatment preferences and acceptability.
Interested in participating?
Request Info18 year and older
All sexes
Observational
Washington D.C., District of Columbia, 20010, United States
Location status: Recruiting
Christopher Riegner, MPH
CONTACT
Inger Ljungberg, MPH
CONTACT
Participants in this study will engage in an in-depth qualitative semi-structured interview process designed to explore their experiences with intravesical instillation practices. Each participant will complete a one-hour interview, during which they will be asked about their personal routines, decision-making factors, and perceptions related to bladder instillations. To ensure accuracy of interpretation, participants may also be invited to take part in brief follow-up discussions lasting no more than 30 minutes each. These follow-up interactions will occur within 12 months of the initial interview, and the total participation time will not exceed 2.5 hours over the study period.
All interviews will be audio-recorded, transcribed, reviewed for accuracy, and analyzed using a secure, cloud-based qualitative data analysis platform that allows linked review of audio and transcript files. Interviews will continue until data saturation is reached, meaning no new concepts emerge from additional participants.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Criteria for patients:
Criteria for caregivers:
Exclusion criteria
Time frame: 12 months
Qualitative interviews will be coded, and themes how to advance intravesical instillation for urinary health will emerge.
Contact information is provided by the study sponsor or research team.
Christopher Riegner, MPH
CONTACT
Inger Ljungberg, MPH
CONTACT
Medstar Health Research Institute
Other
Intravesical Gentamicin Coupled With Lactobacillus Rhamnosus for Urinary Health- Early Career
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05230511
Central Nervous System Diseases, Female Urogenital Diseases
Washington D.C., District of Columbia, United States
View Trial DetailsNCT06515223
Central Nervous System Diseases, Colonic Diseases
Stanmore, United Kingdom
View Trial DetailsNCT04936217
Central Nervous System Diseases, Female Urogenital Diseases
Nîmes, Gard, France
View Trial DetailsNCT04248322
Central Nervous System Diseases, Female Urogenital Diseases
Washington D.C., District of Columbia, United States
View Trial Details